Cardurion Pharmaceuticals to Provide Update on CaMKII Inhibitor Program at the American Heart Association’s Scientific Sessions 2023
Next Generation Cardiovascular Biotech to Present non-clinical Data on Two of its Novel, Potent, and Highly Selective CaMKII Inhibitors First Company to Study a CaMKII Inhibitor in a Clinical Trial BURLINGTON, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the […]
Cardurion Pharmaceuticals Welcomes Emma Reeve as Independent Board Director and Audit Chair
Accomplished CFO and Board Leader to Provide Independent Leadership to Deliver on Company’s Growth Strategy BURLINGTON, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of Emma Reeve as an independent board […]
Cardurion Pharmaceuticals Further Bolsters Leadership Team with Appointment of Stephen Migausky as General Counsel
Experienced Life Sciences Executive Brings 15 Years of Legal, Corporate Strategy, and Business Development Experience BURLINGTON, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of Stephen Migausky as Senior Vice President […]
Cardurion Pharmaceuticals Bolsters Leadership Team with Appointment of Elizabeth Radcliffe as Chief Financial Officer
Strategic Finance Leader Brings Deep Biopharmaceutical Industry Experience and Track Record of Successful Leadership BURLINGTON, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced the appointment of Elizabeth Radcliffe as Chief Financial Officer. A […]
Cardurion Pharmaceuticals Announces Dosing of Patients in CARDINAL-HF, a Phase 2 Clinical Trial of its PDE9 inhibitor in Heart Failure
CARDINAL-HF is the first Phase 2 proof-of-concept trial of a PDE9 inhibitor in heart failure Large-scale trial builds upon encouraging data generated in Cardurion’s Phase 1b trial CARDINAL-HF will examine the effects of CRD-740, Cardurion’s PDE9 inhibitor, in both types of heart failure and in key subsets of these patients BOSTON – July 19, 2022 […]
Cardurion Pharmaceuticals Enhances Leadership Team with Appointment of Marcia Moore as Chief Operating Officer
Brings More Than 30 Years of Pharmaceutical and Biotechnology Leadership Experience Supports Cardurion’s Continued Advancement of Growing Pipeline of Cardiovascular Drug Candidates BOSTON – February 16, 2022 – Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of heart failure […]
Cardurion Pharmaceuticals Announces Investment of up to $300 Million from Bain Capital
Investment to support Cardurion’s further evolution into a cardiovascular leader BOSTON – October 27, 2021 – Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced it has received a private investment […]
Cardurion Pharmaceuticals Announces Appointment of Howard K. Surks, M.D., as Chief Scientific Officer and Head, Translational Medicine
Appointment reflects progress of Company’s early-stage pipeline toward the clinic BOSTON, Mass., December 14, 2020 – Cardurion Pharmaceuticals, Inc. (Cardurion), a Boston-based, clinical-stage biotechnology company focused on discovering and developing next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced the appointment of Howard K. Surks, M.D., as chief scientific officer […]
Cardurion Pharmaceuticals Announces Appointment of Chris Morabito, M.D., as Chief Medical Officer
Appointment reflects growing strength and diversity of Cardurion’s pipeline July 08, 2020 08:00 AM Eastern Daylight Time BOSTON–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (Cardurion), a Boston-based, clinical-stage biotechnology company focused on discovering and developing next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced the appointment of Chris Morabito, M.D., as chief medical officer […]
Cardurion Pharmaceuticals Announces Appointment of Peter Lawrence as President and Chief Executive Officer
April 15, 2020 07:30 AM Eastern Daylight Time BOSTON – (BUSINESS WIRE) – Cardurion Pharmaceuticals, Inc. (Cardurion), a Boston-based, clinical-stage biotechnology company focused on discovering and developing next-generation therapeutics for the treatment of heart failure and other cardiovascular diseases, today announced the appointment of Peter S. Lawrence as president and chief executive officer. Mr. Lawrence joins Cardurion after […]
